newsfilter
← Latest News
GlobeNewswire·

MapLight Announces Topline Results from Phase 2 IRIS Study for ML-004 in Autism Spectrum Disorder

  • The IRIS Phase 2 trial failed to meet its primary endpoint for social communication deficits in autism spectrum disorder (ASD).
  • A prespecified analysis showed ML-004 significantly improved irritability in adolescents (ages 12-17) with moderate to severe baseline irritability (ABC-I ≥ 16) compared to placebo.
  • Adolescents with greater baseline irritability demonstrated the most pronounced treatment effects on both caregiver-reported ABC-I (effect size 1.33, p=0.013) clinician-rated CGI-I (effect size 1.08, p=0.036).
  • ML-004 was generally well-tolerated with no severe or serious adverse events in the active treatment arm.
  • No extrapyramidal events were observed, mean weight gain was lower with ML-004 than placebo, common side effects included headache, nausea, somnolence, vomiting, fatigue, and dizziness.
  • The company plans to engage with the FDA in an End-of-Phase 2 meeting to determine the future clinical development path for ML-004.
  • MapLight Therapeutics remains well-capitalized ahead of expected topline results from the Phase 2 ZEPHYR trial for ML-007C-MA in schizophrenia, anticipated by mid-August 2026.
  • The company hosted a live webcast at 8:00 AM ET on June 22, 2026, to discuss the IRIS trial results.